Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martín, Noelia Jáñez Martínez, Frankie A. Holmes et al.|The Lancet Oncology|2017Cited by 594
Abstract 1265: Tissue is alive: Preserving phosphoproteins and tissue morphology in clinical trial samplesClaudius Mueller, Virginia Espina, Amy VanMeter et al.|Cancer Research|2012Cited by 0